Results 1 to 10 of about 76,869 (253)

Toxoplasma effector GRA15-driven CCL5 secretion enhances brain parasite load through microvascular sequestration of phagocytes [PDF]

open access: yesmBio
Toxoplasma gondii exploits host phagocytes to disseminate systemically and establish infection in the central nervous system (CNS). Yet, the mechanisms governing the interaction between parasitized phagocytes and the brain endothelium remain elusive ...
Elena Afanaseva   +2 more
doaj   +2 more sources

Induction of CCL8/MCP-2 by mycobacteria through the activation of TLR2/PI3K/Akt signaling pathway. [PDF]

open access: yes, 2012
Pleural tuberculosis (TB), together with lymphatic TB, constitutes more than half of all extrapulmonary cases. Pleural effusions (PEs) in TB are representative of lymphocytic PEs which are dominated by T cells.
Chen, Jianxia   +14 more
core   +24 more sources

CCL5 activation of CCR5 regulates cell metabolism to enhance proliferation of breast cancer cells [PDF]

open access: yesOpen Biology, 2016
In earlier studies, we showed that CCL5 enhances proliferation and survival of MCF-7 breast cancer cells in an mTOR-dependent manner and we provided evidence that, for T cells, CCL5 activation of CCR5 results in increased glycolysis and enhanced ATP ...
Darrin Gao   +2 more
doaj   +1 more source

Effect of azithromycin on migration of peripheral blood NK cells from patients with chronic obstructive pulmonary disease

open access: yesМедицинская иммунология, 2023
Currently, no drugs have been identified that could slow progression of chronic obstructive pulmonary disease (COPD), or have a significant impact on patient mortality.
A. G. Kadushkin   +4 more
doaj   +1 more source

Anti-inflammatory Activity of the Protein Z-Dependent Protease Inhibitor

open access: yesTH Open, 2021
The protein Z (PZ)-dependent plasma protease inhibitor (ZPI) is a glycoprotein that inhibits factor XIa and, in the presence of PZ, FXa. Recently, ZPI has been shown to be an acute-phase protein (APP).
Mahita Razanakolona   +10 more
doaj   +1 more source

CCL5 production in lung cancer cells leads to an altered immune microenvironment and promotes tumor development

open access: yesOncoImmunology, 2022
Current immunotherapies for lung cancer are only effective in a subset of patients. Identifying tumor-derived factors that facilitate immunosuppression offers the opportunity to develop novel strategies to supplement and improve current therapeutics.
Etienne S. Melese   +21 more
doaj   +1 more source

CCL5 Release by CCR9+ CD8 T Cells: A Potential Contributor to Immunopathology of Primary Sjögren’s Syndrome

open access: yesFrontiers in Immunology, 2022
IntroductionIncreased CCL5 expression and CD8 T cells have been shown to be pivotal regulators of immunopathology in primary Sjögren’s syndrome (pSS) and pSS-like disease. Increased CCL5 expression by CCR9+ CD4 T cells has previously been implicated as a
Anneline C. Hinrichs   +8 more
doaj   +1 more source

Firing up the cold tumors by targeting Vps34

open access: yesOncoImmunology, 2020
Cancer immunotherapy based on anti-PD-1/PD-L1 blockade is particularly effective in responding to patients with hot tumors. These tumors are characterized by the accumulation of proinflammatory cytokines and T cell infiltration.
Bassam Janji   +4 more
doaj   +1 more source

Blockade of Autocrine CCL5 Responses Inhibits Zika Virus Persistence and Spread in Human Brain Microvascular Endothelial Cells

open access: yesmBio, 2021
Zika virus (ZIKV) is a neurovirulent flavivirus that uniquely causes fetal microcephaly, is sexually transmitted, and persists in patients for up to 6 months.
Megan C. Mladinich   +4 more
doaj   +1 more source

Intrahepatic Expression of C-C Motif ligand 5 in Patients with Chronic Hepatitis B

open access: yesThe Turkish Journal of Gastroenterology, 2021
Background/Aims: C-C motif ligand 5 (CCL5) is reported to play a key role in acute and chronic liver diseases. However, the association between the CCL5 and chronic hepatitis B (CHB) remains to be explored.
Xiang-An Zhao   +7 more
doaj   +1 more source

Home - About - Disclaimer - Privacy